A Randomized, Placebo-Controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Multiple Doses of BMS-986165 in Subjects With Active Psoriatic Arthritis (PsA)
A Randomized, Placebo-Controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Multiple Doses of BMS-986165 in Subjects With Active Psoriatic Arthritis (PsA)
The main purpose of study is to assess the dose-response relationship of BMS-986165 (Dose A or Dose B once daily [QD]) at Week 16 in the treatment of participants with active PsA.
The study is intended to evaluate the safety and efficacy of BMS-986165 Dose A or B once daily (QD) compared with placebo in adults with active PsA. The primary endpoint is american college of rheumatology (ACR) 20 response at Week 16 (Part A).
Inclusion Criteria:
Exclusion Criteria:
Charlotte, North Carolina 28204, United States
Hlu?, 748 01, Czechia
Praha 11 Chodov, 148 00, Czechia
Hamburg, 20095, Germany
Bia?ystok, 15-351, Poland
Elblag, 82-300, Poland
Krak, 30-033, Poland
Krak, 30-510, Poland
Petrozavodsk, 185019, Russia
Yarolavl, 150003, Russia